Siglec and anti-Siglec therapies

Gavuthami Murugesan; Bernd Weigle; Paul R. Crocker

doi:10.1016/j.cbpa.2021.01.001

Siglec and anti-Siglec therapies

Gavuthami Murugesan, Bernd Weigle, Paul R. Crocker (Lead / Corresponding author)

Cell and Developmental Biology

Research output: Contribution to journal › Review article › peer-review

22 Citations (Scopus)

Abstract

Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of receptors that bind sialic acids in specific linkages on glycoproteins and glycolipids. Siglecs play roles in immune signalling and exhibit cell-type specific expression and endocytic properties. Recent studies suggest that Siglecs are likely to function as immune checkpoints that regulate responses in cancers and inflammatory diseases. In this review, we discuss strategies to target the Siglec-sialic acid axis in human diseases, particularly cancer, and the possibility of exploiting them for therapeutic intervention.

Original language	English
Pages (from-to)	34-42
Number of pages	9
Journal	Current Opinion in Chemical Biology
Volume	62
Early online date	16 Feb 2021
DOIs	https://doi.org/10.1016/j.cbpa.2021.01.001
Publication status	Published - Jun 2021

Keywords

Siglec
Sialic acid
Cancer
Inflammation
Immune checkpoint

ASJC Scopus subject areas

Analytical Chemistry
Biochemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cbpa.2021.01.001Licence: Elsevier User Licence

Cite this

@article{db52f9c2e74b44fa8b708e5f2ed0e6ab,

title = "Siglec and anti-Siglec therapies",

abstract = "Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of receptors that bind sialic acids in specific linkages on glycoproteins and glycolipids. Siglecs play roles in immune signalling and exhibit cell-type specific expression and endocytic properties. Recent studies suggest that Siglecs are likely to function as immune checkpoints that regulate responses in cancers and inflammatory diseases. In this review, we discuss strategies to target the Siglec-sialic acid axis in human diseases, particularly cancer, and the possibility of exploiting them for therapeutic intervention.",

keywords = "Siglec, Sialic acid, Cancer, Inflammation, Immune checkpoint",

author = "Gavuthami Murugesan and Bernd Weigle and Crocker, {Paul R.}",

year = "2021",

month = jun,

doi = "10.1016/j.cbpa.2021.01.001",

language = "English",

volume = "62",

pages = "34--42",

journal = "Current Opinion in Chemical Biology",

issn = "1367-5931",

publisher = "Elsevier",

}

TY - JOUR

T1 - Siglec and anti-Siglec therapies

AU - Murugesan, Gavuthami

AU - Weigle, Bernd

AU - Crocker, Paul R.

PY - 2021/6

Y1 - 2021/6

N2 - Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of receptors that bind sialic acids in specific linkages on glycoproteins and glycolipids. Siglecs play roles in immune signalling and exhibit cell-type specific expression and endocytic properties. Recent studies suggest that Siglecs are likely to function as immune checkpoints that regulate responses in cancers and inflammatory diseases. In this review, we discuss strategies to target the Siglec-sialic acid axis in human diseases, particularly cancer, and the possibility of exploiting them for therapeutic intervention.

AB - Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of receptors that bind sialic acids in specific linkages on glycoproteins and glycolipids. Siglecs play roles in immune signalling and exhibit cell-type specific expression and endocytic properties. Recent studies suggest that Siglecs are likely to function as immune checkpoints that regulate responses in cancers and inflammatory diseases. In this review, we discuss strategies to target the Siglec-sialic acid axis in human diseases, particularly cancer, and the possibility of exploiting them for therapeutic intervention.

KW - Siglec

KW - Sialic acid

KW - Cancer

KW - Inflammation

KW - Immune checkpoint

UR - http://www.scopus.com/inward/record.url?scp=85100968482&partnerID=8YFLogxK

U2 - 10.1016/j.cbpa.2021.01.001

DO - 10.1016/j.cbpa.2021.01.001

M3 - Review article

C2 - 33607404

SN - 1367-5931

VL - 62

SP - 34

EP - 42

JO - Current Opinion in Chemical Biology

JF - Current Opinion in Chemical Biology

ER -

Siglec and anti-Siglec therapies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this